Over the past decades,transcatheter therapy has become the primary option for the treatment of simple congenital heart diseases with the advantages of minimal invasiveness and rapid recovery.However,currently used met...Over the past decades,transcatheter therapy has become the primary option for the treatment of simple congenital heart diseases with the advantages of minimal invasiveness and rapid recovery.However,currently used metal occluders may cause nickel allergies,inflammation,and erosion.In the treatment of ventricular septal defects(VSD),due to the close proximity of the electrical conduction tissue,implantation of conventional occluders may cause conduction abnormalities.Complete atrioventricular block can occur in up to 2%of patients undergoing percutaneous perimembranous VSD closure with conventional devices[1].The timing of this event varies,ranging from immediate/intraprocedural to years after the procedure.Most commonly,it is observed within the first five days[1],however,late-onset atrioventricular block is fairly common.For this reason,no perimembranous VSD closure device has been approved by the US Food and Drug Administration[2].The complicated anatomical structure of VSDs and its anatomical relationship to the atrioventricular node complicates device design and development.In this context,bioresorbable occluders have potential advantages.It is conceivable that,due to implant degradation over time and native cardiac tissue coverage,surrounding tissue compression and persistent arrhythmias are less prevalent.展开更多
文摘Over the past decades,transcatheter therapy has become the primary option for the treatment of simple congenital heart diseases with the advantages of minimal invasiveness and rapid recovery.However,currently used metal occluders may cause nickel allergies,inflammation,and erosion.In the treatment of ventricular septal defects(VSD),due to the close proximity of the electrical conduction tissue,implantation of conventional occluders may cause conduction abnormalities.Complete atrioventricular block can occur in up to 2%of patients undergoing percutaneous perimembranous VSD closure with conventional devices[1].The timing of this event varies,ranging from immediate/intraprocedural to years after the procedure.Most commonly,it is observed within the first five days[1],however,late-onset atrioventricular block is fairly common.For this reason,no perimembranous VSD closure device has been approved by the US Food and Drug Administration[2].The complicated anatomical structure of VSDs and its anatomical relationship to the atrioventricular node complicates device design and development.In this context,bioresorbable occluders have potential advantages.It is conceivable that,due to implant degradation over time and native cardiac tissue coverage,surrounding tissue compression and persistent arrhythmias are less prevalent.
